NCT02331173

Clinical Evaluation of Patients With X-linked Retinoschisis

Clinical Evaluation of Patients With X-linked Retinoschisis (XLRS)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 66 (actual)
• Sponsor: Beacon Therapeutics · Industry
• Sex: Male
• Age: 7 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.

Detailed description

The objective of the study is to evaluate subjects with XLRS in a clinical setting and gather data on disease progression. The data from this study will enhance the understanding of the natural history of this rare disease and will facilitate appropriately powered safety studies in a future gene therapy trial in humans.

Conditions

• X-linked Retinoschisis
• XLRS

Interventions

Type	Name	Description
DRUG	Dorzolamide 2% TID or brinzolamide 1% TID	Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows: * Topical dorzolamide 2% three times per day * Topical brinzolamide 1% three times per day

Timeline

• Start date: 2012-11-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2015-01-06
• Last updated: 2017-11-17

Locations

3 sites across 1 country: United States